Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 29, 2007

Codexis Licenses Drug Metabolite Profiling and Lead Diversification Tool

  • Codexis licensed intellectual property from the California Institute of Technology for preparing and identifying drug metabolites. The company plans to incorporate this technology in the development of new R&D productivity tools.

    The licensed technology is based on development of a family of diverse variants of bacterial cytochrome P450 enzymes. “This enzyme family can facilitate identification of safer, more efficacious drugs earlier in the drug development process by expediting the production of potential human metabolites of drug candidates,” explains Peter Seufer-Wasserthal, Ph.D., vp and general manager, Codexis Pharma Services Group.

    “Additionally, this technology can be used for lead diversification and complements the human cytochrome biocatalyst products and services at BioCatalytics, acquired by Codexis in July,” Dr. Seufer-Wasserthal remarked.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »